ArticleFrontiers in pharmacology2021

Risk of Cardiovascular Events and Medical Cost of Dapagliflozin and Dipeptidyl Peptidase-4 Inhibitors.

Jong-Mi Seong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.